ShuGuang Hospital

Company snapshot

ShuGuang Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Liver Cirrhosis Due to Hepatitis B Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ShuGuang Hospital. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ShuGuang Hospital.

1. Jun 8, 2026 Clinical update

   Entecavir + Placebo — Approved

View all clinical trial activity →

• What is ShuGuang Hospital?

  ShuGuang Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Liver Cirrhosis Due to Hepatitis B Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

• Is ShuGuang Hospital publicly traded?

  ShuGuang Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ShuGuang Hospital develop or market?

  We link 2 drug profile(s) where ShuGuang Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shuguang-hospital#company-drugs.

• What are the latest developments for ShuGuang Hospital?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ShuGuang Hospital focus on?

  ShuGuang Hospital focuses on Liver Cirrhosis Due to Hepatitis B Virus based on our analysis of their pipeline programs and drug development activities.